MyoKardia Inc. (MYOK) Trading Down 11.4%
MyoKardia Inc. (NASDAQ:MYOK)’s share price was down 11.4% during mid-day trading on Monday . The company traded as low as $18.51 and last traded at $18.51, with a volume of 140,003 shares traded. The stock had previously closed at $20.88.
A number of equities analysts have issued reports on MYOK shares. Wells Fargo & Co. restated a “buy” rating on shares of MyoKardia in a report on Sunday, September 11th. Zacks Investment Research upgraded MyoKardia from a “sell” rating to a “hold” rating in a report on Tuesday, August 23rd. Credit Suisse Group AG restated a “buy” rating and set a $20.00 target price (up previously from $16.00) on shares of MyoKardia in a report on Tuesday, July 12th. BMO Capital Markets started coverage on MyoKardia in a report on Wednesday, July 20th. They set an “outperform” rating and a $28.00 target price on the stock. Finally, Wedbush restated an “outperform” rating and set a $22.00 target price on shares of MyoKardia in a report on Tuesday, August 9th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. MyoKardia currently has an average rating of “Buy” and a consensus price target of $23.50.
The firm’s market cap is $501.76 million. The firm’s 50-day moving average is $19.96 and its 200-day moving average is $14.39.
MyoKardia (NASDAQ:MYOK) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.04. MyoKardia had a negative return on equity of 62.91% and a negative net margin of 222.21%. The business had revenue of $3.55 million for the quarter, compared to the consensus estimate of $3.55 million. The business’s quarterly revenue was up .0% on a year-over-year basis. On average, equities analysts forecast that MyoKardia Inc. will post ($1.52) earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of the company. Teachers Advisors Inc. boosted its position in shares of MyoKardia by 185.7% in the second quarter. Teachers Advisors Inc. now owns 18,223 shares of the company’s stock worth $226,000 after buying an additional 11,845 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of MyoKardia by 144.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 83,989 shares of the company’s stock worth $1,041,000 after buying an additional 49,603 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of MyoKardia by 80.2% in the second quarter. BlackRock Fund Advisors now owns 290,293 shares of the company’s stock worth $3,600,000 after buying an additional 129,164 shares during the last quarter. BlackRock Investment Management LLC boosted its position in shares of MyoKardia by 109.8% in the second quarter. BlackRock Investment Management LLC now owns 42,352 shares of the company’s stock worth $525,000 after buying an additional 22,169 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of MyoKardia by 130.8% in the second quarter. Vanguard Group Inc. now owns 314,800 shares of the company’s stock worth $3,904,000 after buying an additional 178,431 shares during the last quarter. 36.67% of the stock is owned by institutional investors and hedge funds.
MyoKardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.